Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | HTR3A | P46098 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640493 | 1.00 | HRH3 (1.00) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| SCHEMBL1639614 | 0.89 | HRH3 (0.80) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| SCHEMBL1639611 | 0.89 | HRH3 (0.80) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| Irdabisant SCHEMBL1376185 | 0.82 | HRH3 (1.00) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| Irdabisant SCHEMBL117723 | 0.82 | HRH3 (1.00) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| Irdabisant SCHEMBL118744 | 0.82 | HRH3 (1.00) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| Irdabisant SCHEMBL16040431 | 0.81 | HRH3 (0.98) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| Irdabisant SCHEMBL16040208 | 0.81 | HRH3 (0.98) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| Irdabisant SCHEMBL16040206 | 0.81 | HRH3 (0.98) | HRH3CHRM2SLC6A2ADRA1AHTR3A | |
| SCHEMBL1923148 | 0.80 | HRH3 (1.00) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | HRH3 1/4885CHRM2 34/4885SLC6A2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.